Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid | Zendy

Hasan Naz | Zendy; Vahap Aslan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid

Author(s) -

Hasan Naz,

Vahap Aslan

Publication year - 2009

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.559

Subject(s) - ursodeoxycholic acid , ribavirin , medicine , autoimmune thrombocytopenia , chronic hepatitis , pegylated interferon , gastroenterology , autoimmune hepatitis , adverse effect , immunology , hepatitis c virus , virus , platelet , hepatitis

Pegylated interferon (PEG-IFN) alpha and ribavirin therapy has become the standard treatment in chronic hepatitis C virus (HCH)-infected patients. While thrombocytopenia associated with IFN use is frequently observed among these patients, autoimmune thrombocytopenia is one of the rarely observed adverse effects. In the present report, we present a case with chronic HCV infection in which autoimmune thrombocytopenia developed at week 7 of PEG-IFN alpha 2b plus ribavirin therapy. The patient subsequently received ursodeoxycholic acid (UDCA) treatment. Although there is not an adequate number of studies on this subject, it was concluded that the use of UDCA in cases of autoimmune thrombocytopenia that have developed due to PEG-IFN treatment in chronic HCV infection is a favorable option.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research